Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Michelle Kreidt

Physician Assistant Santa Ana, CA Physician Assistant

NPI 1740840487 CMS profile 10475574

620 S Main St, Santa Ana, CA 92701

Open in the dashboard

General payments

$12,658

544 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Michelle Kreidt of Santa Ana, CA is reported in the CMS Open Payments database as having received $12,658 across 544 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 98th percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,230 93
2024 General $2,050 92
2023 General $2,337 95
2022 General $2,294 109
2021 General $3,747 155

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Michelle Kreidt
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to Michelle Kreidt were reported at $2,230. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year Michelle Kreidt Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $3,747 $132 $37–$438 $132
2022 $2,294 $155 $48–$522 $149
2023 $2,337 $167 $52–$557 $160
2024 $2,050 $178 $55–$600 $164
2025 $2,230 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AstraZeneca Pharmaceuticals LP $2,284 98 payments
  2. Lilly USA, LLC $1,214 52 payments
  3. Novo Nordisk Inc $1,041 56 payments
  4. Boehringer Ingelheim Pharmaceuticals, Inc. $1,012 45 payments
  5. Amgen Inc. $910 40 payments
  6. Biohaven Pharmaceuticals, Inc. $838 3 payments
  7. Bayer HealthCare Pharmaceuticals Inc. $610 20 payments
  8. AbbVie, Inc. $557 26 payments
  9. Takeda Pharmaceuticals U.S.A., Inc. $404 9 payments
  10. GlaxoSmithKline, LLC. $389 20 payments
  11. Other $3,397 175 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $11,763 542 payments
  2. Consulting Fee $800 1 payment
  3. Education $95 1 payment
Products named General payments · program years 2021–2025
  1. FARXIGA $1,126 53 payments
  2. NURTEC ODT $838 3 payments
  3. Ozempic $616 37 payments
  4. Kerendia $610 20 payments
  5. AIRSUPRA $590 25 payments
  6. RYBELSUS $550 34 payments
  7. JARDIANCE Diabetes $547 25 payments
  8. JARDIANCE Diabetes $533 21 payments
  9. MOUNJARO $472 17 payments
  10. Repatha $360 15 payments
  11. Other $9,620 456 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 76 drugs

Part D claims

3,088

Median for Physician Assistant: 241

Drug cost

$395,026

Median for Physician Assistant: $4,110

Branded share of claims

24%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Trulicity Dulaglutide Brand 61 $72,467
Rybelsus Semaglutide Brand 27 $55,324
Ozempic Semaglutide Brand 39 $52,170
Farxiga Dapagliflozin Propanediol Brand 31 $41,108
Mounjaro Tirzepatide Brand 28 $29,347
Januvia Sitagliptin Phosphate Brand 30 $21,480
Jardiance Empagliflozin Brand 21 $20,484
Eliquis Apixaban Brand 12 $15,870
Soliqua 100-33 Insulin Glargine/Lixisenatide Brand 14 $13,923
Vascepa Icosapent Ethyl Brand 31 $13,783

The 10 drugs with the highest cost, of 76 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 32 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
AIRSUPRA
  • AstraZeneca Pharmaceuticals LP $289
$289 — —
FARXIGA
  • AstraZeneca Pharmaceuticals LP $179
$179 31 —
Kerendia
  • Bayer HealthCare Pharmaceuticals Inc. $173
$173 — —
JARDIANCE
  • Lilly USA, LLC $68
  • Boehringer Ingelheim Pharmaceuticals, Inc. $51
$119 21 —
MOUNJARO
  • Lilly USA, LLC $107
$107 28 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 32 with Patron

Records

544 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record